Form 4: Tarsus Pharmaceuticals Director Lin Elizabeth Yeu Reports Stock Transactions

Director Lin Elizabeth Yeu of Tarsus Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On June 24, 2024, Lin Elizabeth Yeu, a director of Tarsus Pharmaceuticals, reported transactions involving the company's stock.
• Yeu acquired 3,350 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Following the reported transactions, Yeu directly owns 5,350 shares of common stock.
• Yeu also indirectly owns 12,040 shares through a 401(k) plan and 15,866 shares through a spouse's Roth IRA.
• The RSUs were granted on June 22, 2023, and vested on the one-year anniversary, contingent upon continuous service as a non-employee director.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It is standard practice for directors and officers to report changes in their beneficial ownership of company stock.

Stakeholder Impact

• The transactions reported may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates